RS50073B - Modifikovani himerni polipeptidi sa poboljšanim farmakokinetičkim osobinama - Google Patents

Modifikovani himerni polipeptidi sa poboljšanim farmakokinetičkim osobinama

Info

Publication number
RS50073B
RS50073B YUP-869/01A YUP86901A RS50073B RS 50073 B RS50073 B RS 50073B YU P86901 A YUP86901 A YU P86901A RS 50073 B RS50073 B RS 50073B
Authority
RS
Serbia
Prior art keywords
flt1
domain
vegf
fcacl
vegf receptor
Prior art date
Application number
YUP-869/01A
Other languages
English (en)
Serbian (sr)
Inventor
Nicholas J. Papadopoulos
Samuel Davis
George D. Yancopoulos
Original Assignee
Regeneron Pharmaceuticals I.N.C.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22480568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS50073(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharmaceuticals I.N.C., filed Critical Regeneron Pharmaceuticals I.N.C.,
Publication of YU86901A publication Critical patent/YU86901A/sh
Publication of RS50073B publication Critical patent/RS50073B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
YUP-869/01A 1999-06-08 2000-05-23 Modifikovani himerni polipeptidi sa poboljšanim farmakokinetičkim osobinama RS50073B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13813399P 1999-06-08 1999-06-08

Publications (2)

Publication Number Publication Date
YU86901A YU86901A (sh) 2004-05-12
RS50073B true RS50073B (sr) 2009-01-22

Family

ID=22480568

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-869/01A RS50073B (sr) 1999-06-08 2000-05-23 Modifikovani himerni polipeptidi sa poboljšanim farmakokinetičkim osobinama

Country Status (32)

Country Link
EP (2) EP1544299B1 (OSRAM)
JP (2) JP4723140B2 (OSRAM)
KR (1) KR100659477B1 (OSRAM)
CN (3) CN103349781B (OSRAM)
AT (2) ATE293164T1 (OSRAM)
AU (2) AU779303B2 (OSRAM)
BE (1) BE2013C029I2 (OSRAM)
BR (2) BRPI0011407B8 (OSRAM)
CA (1) CA2376379C (OSRAM)
CY (2) CY1108883T1 (OSRAM)
CZ (2) CZ302689B6 (OSRAM)
DE (2) DE60019415T2 (OSRAM)
DK (2) DK1183353T3 (OSRAM)
ES (2) ES2237429T3 (OSRAM)
FR (1) FR13C0028I2 (OSRAM)
HR (1) HRP20010908B1 (OSRAM)
HU (3) HU230159B1 (OSRAM)
IL (3) IL146890A0 (OSRAM)
LT (1) LTC1183353I2 (OSRAM)
LU (1) LU92195I2 (OSRAM)
ME (2) MEP3208A (OSRAM)
MX (1) MXPA01012630A (OSRAM)
NO (4) NO330775B1 (OSRAM)
NZ (1) NZ515913A (OSRAM)
PL (1) PL208247B1 (OSRAM)
PT (2) PT1544299E (OSRAM)
RS (1) RS50073B (OSRAM)
RU (1) RU2265661C2 (OSRAM)
SK (1) SK287332B6 (OSRAM)
UA (1) UA74146C2 (OSRAM)
WO (1) WO2000075319A1 (OSRAM)
ZA (1) ZA200110068B (OSRAM)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6710174B2 (en) 2001-09-13 2004-03-23 Isis Pharmaceuticals, Inc. Antisense inhibition of vascular endothelial growth factor receptor-1 expression
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US6833349B2 (en) * 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
AU2002248372B8 (en) 2001-01-19 2008-03-20 Vegenics Limited FLT4(VEGFR-3) as a target for tumor imaging and anti-tumor therapy
US6734017B2 (en) 2001-09-28 2004-05-11 Isis Pharmaceuticals, Inc. Antisense modulation of vascular endothelial growth factor receptor-2 expression
ES2362648T3 (es) 2002-05-04 2011-07-08 Acorda Therapeutics, Inc. Composiciones y métodos para promover la proyección neuronal.
DE602004004883T2 (de) 2003-03-28 2007-11-15 Regeneron Pharmaceuticals, Inc. Vegf-antagonisten zur behandlung von diabetes
MXPA05012307A (es) 2003-05-16 2006-07-03 Acorda Therapeutics Inc Mutantes que degradan proteoglicanos para tratamiento del snc.
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
AU2004247025B8 (en) * 2003-05-16 2011-06-30 Acorda Therapeutics, Inc. Fusion proteins for the treatment of CNS
EP1626989A2 (en) * 2003-05-28 2006-02-22 Regeneron Pharmaceuticals, Inc. Method of treating corneal transplant rejection by using vegf antagonists
US7186699B2 (en) 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
US7354578B2 (en) 2003-06-06 2008-04-08 Regeneron Pharmaceuticals, Inc. Method of tumor regression with VEGF inhibitors
US7399612B2 (en) 2003-06-30 2008-07-15 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
AR046510A1 (es) * 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
US20050112061A1 (en) * 2003-08-06 2005-05-26 Jocelyn Holash Use of a VEGF antagonist in combination with radiation therapy
EP1750757B1 (en) 2004-05-18 2013-03-13 Acorda Therapeutics, Inc. Methods of purifying chondroitinase and stable formulations thereof
DK1767546T3 (da) 2004-06-08 2012-04-23 Chengdu Kanghong Biotechnologies Co Ltd Angiogenese-inhiberende kimært protein og dets anvendelse
EP2583685A1 (en) 2004-06-10 2013-04-24 Regeneron Pharmaceuticals, Inc. Method of administering and using VEGF inhibitors for the treatment of human cancer
EP1755645A2 (en) * 2004-06-18 2007-02-28 Regeneron Pharmaceuticals, Inc. Vegf inhibitors for the treatment of malignant pleural effusion
AU2005267741A1 (en) * 2004-07-30 2006-02-09 Regeneron Pharmaceuticals, Inc. Methods of treating type I diabetes by blocking VEGF-mediated activity
ES2407859T3 (es) 2004-09-13 2013-06-14 Genzyme Corporation Construcciones multiméricas.
FR2878749B1 (fr) * 2004-12-03 2007-12-21 Aventis Pharma Sa Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives
CA2621047A1 (en) 2005-02-02 2006-08-24 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a vegf inhibitor
ES2633574T3 (es) 2005-03-25 2017-09-22 Regeneron Pharmaceuticals, Inc. Formulaciones de antagonistas de VEGF
CA2623635C (en) 2005-09-26 2013-04-02 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase abci mutants
DK1962895T3 (da) † 2005-12-16 2013-03-04 Regeneron Pharma TERAPEUTISK ANVENDELSE AF EN Dll4-ANTAGONIST OG EN VEGF-HÆMMER TIL HÆMNING AF TUMORVÆKST
FR2895258B1 (fr) 2005-12-22 2008-03-21 Aventis Pharma Sa Combinaison comprenant de la combretastatine et des agents anticancereux
US8216575B2 (en) 2006-03-31 2012-07-10 Chengdu Kanghong Biotechnologies Co., Ltd. Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
CN100502945C (zh) * 2006-03-31 2009-06-24 成都康弘生物科技有限公司 Vegf受体融合蛋白在治疗眼睛疾病中的应用
SI2944306T1 (sl) 2006-06-16 2021-04-30 Regeneron Pharmaceuticals, Inc. Formulacije antagonista VEGF, primerne za intravitrealno dajanje
US7750124B2 (en) 2006-09-29 2010-07-06 Oncomed Pharmaceuticals, Inc. Anti-human DLL4 antibodies and compositions
CA2666536C (en) 2006-10-10 2018-08-07 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase abci mutants
FR2918279B1 (fr) * 2007-07-05 2010-10-22 Aventis Pharma Sa Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan
CN101575379B (zh) * 2008-05-09 2012-05-30 上海抗体药物国家工程研究中心有限公司 可溶性vegfr双功能融合受体、其制备方法及用途
RU2550258C2 (ru) 2008-11-03 2015-05-10 Молекьюлар Партнерс Аг Связывающие белки, ингибирующие взаимодействия vegf-a рецептора
CN101838329A (zh) * 2009-03-18 2010-09-22 嘉和生物药业有限公司 抗血管新生融合蛋白
EP3485908B1 (en) 2009-10-16 2021-08-18 Mereo BioPharma 5, Inc. Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents
TWI510246B (zh) 2010-04-30 2015-12-01 Molecular Partners Ag 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質
US9441029B2 (en) 2010-08-06 2016-09-13 Genzyme Corporation VEGF antagonist compositions and uses thereof
JP6043629B2 (ja) * 2011-01-07 2016-12-14 中外製薬株式会社 抗体の物性を改善させる方法
MX385629B (es) 2011-01-13 2025-03-18 Regeneron Pharma Uso de un antagonista de factor de crecimiento endotelial vascular para tratar trastornos oculares angiogenicos.
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
KR101397088B1 (ko) 2011-06-10 2014-05-19 강원대학교산학협력단 암세포 증식 억제와 혈관신생 억제를 위한 융합 단백질 및 이를 포함한 항암 조성물
JO3370B1 (ar) * 2011-11-10 2019-03-13 Regeneron Pharma طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
CN110078831A (zh) * 2011-12-01 2019-08-02 圆祥生命科技股份有限公司 补体和vegf途径的蛋白质抑制剂及其使用方法
CN103304668B (zh) * 2012-03-12 2015-10-28 江苏健德生物药业有限公司 Ultra-VEGF-trap免疫融合蛋白、其制备方法及其应用
US10568934B2 (en) 2012-05-07 2020-02-25 Allergan, Inc. Method of treating AMD in patients refractory to anti-VEGF therapy
WO2014006113A1 (en) 2012-07-03 2014-01-09 Sanofi Method of treating cancer by effective amounts of aflibercept
AR093445A1 (es) 2012-11-14 2015-06-10 Regeneron Pharma Metodos para tratar el cancer de ovario con antagonistas de dll4
US9745558B2 (en) 2013-02-18 2017-08-29 Vegenics Pty Limited VEGFR-3 ligand binding molecules and uses thereof
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
CN104193828B (zh) * 2013-09-12 2017-04-05 北京韩美药品有限公司 同时阻断her2和vegfr信号通路的重组融合蛋白
CA2927012A1 (en) 2013-11-05 2015-05-14 Allergan, Inc. Method of treating conditions of the eye with an anti-vegf darpin
RU2702748C2 (ru) 2014-05-12 2019-10-11 Формикон Аг Предварительно заполненный пластиковый шприц, содержащий антагонист vegf
SI3170005T1 (sl) 2014-07-18 2019-08-30 Sanofi Postopek napovedovanja izida zdravljenja z afliberceptom, pacienta, pri katerem obstaja sum, da je zbolel za rakom
JP2016036322A (ja) * 2014-08-11 2016-03-22 日本化薬株式会社 血管新生因子と結合するキメラタンパク質
HRP20220066T1 (hr) 2014-12-11 2022-04-15 Bayer Healthcare Llc Liječenje makularne degeneracije povezane sa starenjem s malom aktivnom koroidnom neovaskularizacijskom lezijom
GB201503453D0 (en) 2015-03-01 2015-04-15 Jain Arjun Endothelin-1"sponge"
TW202440903A (zh) 2015-08-04 2024-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法（一）
WO2017046140A1 (en) 2015-09-18 2017-03-23 Bayer Pharma Aktiengesellschaft Treatment regimens for dr and rvo in dependence of the extent of retinal ischemia
KR101936049B1 (ko) * 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
WO2017065559A1 (ko) 2015-10-15 2017-04-20 (주)알테오젠 Igg fc 도메인을 가지는 융합 단백질의 생산방법
BR112018010005A2 (pt) 2015-11-18 2018-11-21 Formycon Ag seringa pré-carregada, e, kit
US11654046B2 (en) 2015-11-18 2023-05-23 Sio2 Medical Products, Inc. Pharmaceutical package for ophthalmic formulations
EP4556023A3 (en) 2015-11-18 2025-10-15 Formycon AG Pre-filled pharmaceutical package comprising a liquid formulation of a vegf-antagonist
EP3377101A4 (en) * 2015-11-19 2019-08-07 Zhuhai Tairuishang Biopharm Ltd. VEGF BINDING METHODS AND COMPOSITIONS
CN114712497B (zh) 2015-12-03 2024-03-22 雷杰纳荣制药公司 抗vegf剂在制备用于治疗新生血管性年龄相关性黄斑变性患者的药物中的用途
US10576128B2 (en) 2016-01-26 2020-03-03 Formycon Ag Liquid formulation of a VEGF antagonist
EP3527225A4 (en) 2016-10-12 2020-06-10 Daiichi Sankyo Company, Limited COMPOSITION WITH ANTI-ROBO4 ANTIBODIES AND OTHER AGENTS
WO2018094316A1 (en) 2016-11-21 2018-05-24 Just Biotherapeutics, Inc. Aflibercept formulations and uses thereof
EP3630062A2 (en) 2017-05-24 2020-04-08 SiO2 Medical Products, Inc. Sterilizable pharmaceutical package for ophthalmic formulations
WO2018215580A1 (en) 2017-05-24 2018-11-29 Formycon Ag Method for sterilizing prefilled plastic syringes containing a vegf antagonist
US20200237997A1 (en) 2017-05-24 2020-07-30 Formycon Ag Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
TW201904610A (zh) 2017-06-14 2019-02-01 德商拜耳製藥公司 用於治療新生血管型青光眼之非抗體vegf拮抗劑
WO2019020777A1 (en) 2017-07-26 2019-01-31 Formycon Ag LIQUID FORMULATION OF A VEGF ANTAGONIST
CA3067735A1 (en) 2017-08-17 2019-02-21 Just Biotherapeutics, Inc. Method of purifying glycosylated protein from host cell galectins and other contaminants
JP7183268B2 (ja) 2017-11-20 2022-12-05 ジャスト－エヴォテック バイオロジックス、インコーポレイテッド 等張化剤としてリジン塩を含有するアフリベルセプト製剤及びその使用
AU2018372235B9 (en) * 2017-11-27 2022-03-10 4D Molecular Therapeutics Inc. Adeno-associated virus variant capsids and use for inhibiting angiogenesis
HUE059827T2 (hu) 2017-11-30 2023-01-28 Regeneron Pharma VEGF-antagonista alkalmazása angiogén szembetegségek kezelésére
CA3084155A1 (en) 2017-12-13 2019-06-20 Regeneron Pharmaceuticals, Inc. Devices and systems for chromatography column bed support management and related methods
US11524053B2 (en) * 2018-01-26 2022-12-13 The Regents Of The University Of California Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents
BR112020017872A2 (pt) 2018-03-02 2020-12-22 Kodiak Sciences Inc. Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos
TW202016125A (zh) * 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
NZ770284A (en) 2018-05-10 2025-11-28 Regeneron Pharma High concentration vegf receptor fusion protein containing formulations
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
CN111378044B (zh) 2018-12-28 2022-07-15 长春金赛药业有限责任公司 抗体融合蛋白、制备方法及其应用
WO2020229584A1 (en) 2019-05-16 2020-11-19 Formycon Ag Method for reducing methionine oxidation in recombinant proteins
CA3150481A1 (en) 2019-09-03 2021-03-11 Amgen Inc. Injection device for drug delivery and packaging for the injection device
JP7704740B2 (ja) 2019-09-16 2025-07-08 アムジエン・インコーポレーテツド 薬物送達デバイスの外部滅菌の方法
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
IL293131A (en) 2019-11-25 2022-07-01 Univ California Long-acting vegf inhibitors for intraocular neovascularization
JP2022548197A (ja) 2019-12-06 2022-11-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｖｅｇｆタンパク質組成物及びその製造方法
WO2021113591A1 (en) 2019-12-06 2021-06-10 Regeneron Pharmaceuticals, Inc. Vegf mini-traps and methods of use thereof
MX2022010177A (es) 2020-02-24 2022-09-12 Amgen Inc Envases y sistemas para su uso durante la esterilizacion externa de dispositivos de administracion de farmacos.
CN115803009A (zh) 2020-05-08 2023-03-14 瑞泽恩制药公司 用于治疗眼病和癌症的vegf阱和微阱及方法
JP2024515220A (ja) 2021-04-26 2024-04-05 セラニーズ・イーブイエイ・パフォーマンス・ポリマーズ・エルエルシー 高分子薬剤化合物の持続放出用の埋め込み型デバイス
EP4145456A1 (en) 2021-09-06 2023-03-08 Bayer AG Prediction of a change related to a macular fluid
WO2023092324A1 (zh) 2021-11-24 2023-06-01 苏州光度生物科技有限公司 多特异性配体结合分子及其应用
KR102764987B1 (ko) 2022-08-02 2025-02-12 주식회사 파노로스바이오사이언스 변형된 융합 단백질 및 이의 용도
JP2025529465A (ja) 2022-09-16 2025-09-04 チールー ファーマシューティカル カンパニー、リミテッド 安定な高濃度自己緩衝医薬組成物
WO2025033876A1 (ko) * 2023-08-04 2025-02-13 주식회사 파노로스바이오사이언스 변형된 융합 단백질과 scFv의 결합체 및 이의 용도
WO2025213011A1 (en) 2024-04-05 2025-10-09 Amgen Inc. Method of assessing stopper movement in a drug delivery device

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506466D0 (en) * 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production

Also Published As

Publication number Publication date
KR20020019070A (ko) 2002-03-09
CZ20014387A3 (cs) 2002-10-16
DE60041159D1 (de) 2009-01-29
PL352246A1 (en) 2003-08-11
DK1183353T3 (da) 2005-08-08
JP2011024595A (ja) 2011-02-10
DK1544299T3 (da) 2009-03-23
HUS1300052I1 (hu) 2016-08-29
CZ303656B6 (cs) 2013-01-30
BRPI0011407B1 (pt) 2018-09-25
ZA200110068B (en) 2002-12-06
CY1108883T1 (el) 2014-07-02
LTPA2013009I1 (lt) 2013-06-25
HRP20010908A2 (en) 2005-04-30
NO332559B1 (no) 2012-10-29
LU92195I2 (fr) 2013-07-15
ATE417928T1 (de) 2009-01-15
NO330775B1 (no) 2011-07-11
PT1183353E (pt) 2005-06-30
NZ515913A (en) 2004-01-30
CN100523187C (zh) 2009-08-05
HK1185798A1 (en) 2014-02-28
CN103349781A (zh) 2013-10-16
EP1544299B1 (en) 2008-12-17
FR13C0028I2 (fr) 2014-05-16
ES2237429T3 (es) 2005-08-01
BR0011407A (pt) 2002-04-02
JP4723140B2 (ja) 2011-07-13
NO20100656L (no) 2002-02-08
UA74146C2 (uk) 2005-11-15
DE60019415D1 (de) 2005-05-19
NO20016036D0 (no) 2001-12-10
CA2376379C (en) 2007-08-07
CN101433715B (zh) 2013-04-17
CY2013019I1 (el) 2015-11-04
IL190234A0 (en) 2008-11-03
PT1544299E (pt) 2009-03-18
JP2003501089A (ja) 2003-01-14
FR13C0028I1 (fr) 2013-06-14
HK1132653A1 (en) 2010-03-05
NO2022060I1 (no) 2022-12-21
ATE293164T1 (de) 2005-04-15
CZ302689B6 (cs) 2011-09-07
CN1369009A (zh) 2002-09-11
EP1183353A1 (en) 2002-03-06
JP5273746B2 (ja) 2013-08-28
MEP3208A (xx) 2010-02-10
ES2319305T3 (es) 2009-05-06
AU5040400A (en) 2000-12-28
AU779303B2 (en) 2005-01-13
WO2000075319A1 (en) 2000-12-14
AU2005201365B2 (en) 2007-08-09
ME00024B (me) 2010-02-10
HRP20010908B1 (en) 2006-05-31
MXPA01012630A (es) 2002-07-22
NO2013010I1 (no) 2013-06-17
YU86901A (sh) 2004-05-12
HK1043388A1 (en) 2002-09-13
IL146890A0 (en) 2002-08-14
CN101433715A (zh) 2009-05-20
DE60019415T2 (de) 2006-03-09
RU2265661C2 (ru) 2005-12-10
EP1544299A1 (en) 2005-06-22
AU2005201365A1 (en) 2005-04-28
HUP0201515A3 (en) 2004-12-28
BE2013C029I2 (OSRAM) 2019-03-06
KR100659477B1 (ko) 2006-12-20
LTC1183353I2 (lt) 2023-02-27
EP1183353B1 (en) 2005-04-13
CA2376379A1 (en) 2000-12-14
IL146890A (en) 2008-07-08
PL208247B1 (pl) 2011-04-29
HUP0201515A2 (en) 2002-08-28
CN103349781B (zh) 2015-04-01
SK287332B6 (sk) 2010-07-07
BRPI0011407B8 (pt) 2021-05-25
HU229156B1 (en) 2013-09-30
HU230159B1 (hu) 2015-09-28
CY2013019I2 (el) 2015-11-04
NO20016036L (no) 2002-02-08
SK17522001A3 (sk) 2003-04-01
NO2013010I2 (no) 2013-05-15

Similar Documents

Publication Publication Date Title
RS50073B (sr) Modifikovani himerni polipeptidi sa poboljšanim farmakokinetičkim osobinama
US7704500B2 (en) Methods of inhibiting ascites formation with modified chimeric VEGF polypeptides
CA2588221C (en) Modified chimeric polypeptides with improved pharmacokinetic properties
HK1043388B (en) Modified chimeric polypeptides with improved pharmacokinetic properties